Pharming Group N.V.
PHAR
$8.51
-$0.07-0.82%
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | 19.33% | 3.58% | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | 19.33% | 3.58% | |
| Cost of Revenue | -- | -- | 44.23% | 368.80% | |
| Gross Profit | -- | -- | 17.01% | -5.64% | |
| SG&A Expenses | -- | -- | 37.52% | 41.45% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | 81.50% | 408.99% | |
| Total Operating Expenses | -- | -- | 38.61% | 42.11% | |
| Operating Income | -- | -- | -1,757.33% | -281.00% | |
| Income Before Tax | -- | -- | -180.04% | -178.15% | |
| Income Tax Expenses | -- | -- | -209.66% | -224.35% | |
| Earnings from Continuing Operations | -- | -- | -177.14% | -170.97% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -- | -- | -177.14% | -170.97% | |
| EBIT | -- | -- | -1,757.33% | -281.00% | |
| EBITDA | -- | -- | -363.87% | -173.36% | |
| EPS Basic | -- | -- | -179.43% | -172.80% | |
| Normalized Basic EPS | -- | -- | -80.66% | -308.54% | |
| EPS Diluted | -- | -- | -208.23% | -182.42% | |
| Normalized Diluted EPS | -- | -- | -70.31% | -320.74% | |
| Average Basic Shares Outstanding | -- | -- | 3.95% | 1.42% | |
| Average Diluted Shares Outstanding | -- | -- | -2.69% | -5.03% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |